Stein_General_0.png

Welcome to ADAA's Professional Community

ADAA is the only multidisciplinary professional organization in mental health that engages the world’s leading experts who focus on anxiety, depression and co-occurring disorders. Engaging a membership of more than 1,800 professionals, ADAA strives to improve patient care by promoting implementation of evidence-based treatments and best practices across disciplines through trainings, continuing education and accelerating dissemination of research into practice.

  ADAA promotes scientific innovation and engages a diverse network of clinicians and basic and clinical anxiety and depression researchers with diverse backgrounds in medicine, psychology, social work, counseling, nursing, neuroscience, genetics, epidemiology, and other disciplines to advance science and new treatments. 

⇒  ADAA member dues help support the free information and resources that are provided to the more than 38 million annual website visitors to www.adaa.org. Membership dues also help fund the research that will one day prevent and cure anxiety, depression and related disorders. 

Member News and Program Updates

"Katrina was excited. She, her sister, Maia, and their mother were on the way to the park to play handball. Suddenly, Maia screamed and collapsed on the ground, wailing. “A fly landed on me! A fly landed on me!” Her mother tried to calm Maia down, but with no success. “I’m sorry.” Katrina’s mom said, “We have to go home.” Katrina was crushed; her sister’s fears had ruined yet another family outing." ADAA member Michelle Witkin, PhD authors this blog post on having a sibling with OCD. 
ADAA members Douglas Mennin, PhD and Sabine Wilhelm, PhD share their insights on CBT for body dysmorphic disorder in this article.
"This study with troriluzole, a drug with a novel mechanism of action, is an important step in helping to elucidate this hypothesis and potentially provide a new treatment modality for GAD," says ADAA member Sanjay Mathew, MD in this article on troriluzole.
"GAD is one of the most common psychiatric disorders seen in the primary care setting and remains under recognized," says ADAA member Sanjay Mathew, MD in this article on Biohaven's Troriluzole trial.